studies

la/mBC - HR-positive - 2nd line (L2), dalpiciclib plus fulvestrant vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsDAWNA-1, 2021 0.42 [0.31; 0.57] 0.42[0.31; 0.57]DAWNA-1, 202110%361NAnot evaluable objective responses (ORR)detailed resultsDAWNA-1, 2021 1.48 [0.87; 2.51] 1.48[0.87; 2.51]DAWNA-1, 202110%361NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-18 10:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1369